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During the 2009–2010 influenza pandemic, an adjuvanted, dose-sparing vaccine was
recommended for most Canadians. We hypothesize that differences exist in the
responses to AS03-adjuvanted, low antigen (Ag) dose versus unadjuvanted, full-dose
vaccines. We investigated the relationship between Ag dose and the oil-in-water emulsion
Adjuvant System AS03. BALB/c mice received two IM doses of AS03A or AS03B with
exaggerated dilutions of A/Uruguay/716/2007 H3N2 split virion vaccine Ag. Immune
responses were assessed 3weeks after the booster. Unadjuvanted “high” (3µg) and
low-dose (0.03–0.003µg) vaccines generated similar serum antibody titers and cytokine
secretion patterns in restimulated splenocytes. Compared to unadjuvanted “high-dose”
vaccination, both AS03A and AS03B-adjuvanted low-dose vaccines tended to elicit higher
serum antibody titers, broader induction of cytokine secretion and generated more
influenza-specific antibody secreting cells and cytokine-secreting CD4 and CD8 T cells in
splenocytes. We show that varying Ag and/or AS03 dose in this influenza vaccination
mouse model can strongly influence both the magnitude and pattern of the immune
response elicited. These findings are highly relevant given the likelihood of expanded use
of adjuvanted, dose-sparing vaccines and raise questions about the use of “standard”
doses of vaccines in pre-clinical vaccine studies.
Keywords: influenza, vaccine, AS03, adjuvant, dose-sparing
Introduction
Vaccines are the most cost-effective method to prevent influenza virus-associated morbidity and
mortality (1); however, they are also least effective in high-risk populations (1). To improve vaccine
efficacy, manufacturers are increasingly turning to adjuvants. During the 2009–2010 A/California
pandemic H1N1 influenza outbreak, the World Health Organization recommended the use of
antigen (Ag)-sparing vaccines (2). In Canada, an Ag-sparing vaccine formulated with AS03 and 25%
of the adult hemagglutinin (HA) dose in unadjuvanted seasonal influenza vaccines was selected for
administration to the majority of Canadians (Arepanrix™; GSK Vaccines, Mississauga, ON, Canada)
(3). A similar vaccine was used in Europe (Pandemrix™, GSK Vaccines, Rixensart, Belgium).
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AS03 is an oil-in-water adjuvant consisting of squalene, alpha-
tocopherol, and polysorbate-80. The greatest experience with
AS03 to date has beenwith vaccines targeting influenza. This work
demonstrated that an AS03-adjuvanted vaccine formulated with
inactivated monovalent influenza A/Vietnam/1194/2004 H5N1 at
low Ag dose (3.8 µg) was able to meet CHMP/FDA licensure
criteria (4). There are two formulations of this adjuvant: AS03A
containing 11.86mg alpha-tocopherol, 10.69mg squalene, and
4.86mg polysorbate-80 per 0.5ml dose; and AS03B, containing
50% of each of the AS03A components. Human studies have
shown that vaccine formulations with AS03A and AS03B generate
comparable short-term antibody responses (5), and that low Ag
doses (3.75 or 1.9 µg) adjuvanted with AS03A or AS03B are non-
inferior in terms of antibody production to unadjuvanted vaccines
at higher Ag doses (6).
In vaccine formulations, AS03 functions to enhance the gener-
ation of Ag-specific memory B cells and polyfunctional CD4+ T
cells (7, 8), induce cross-reactive antibody responses (9). Inmouse
studies, AS03 also induces transient innate immune responses
at the site of injection, which may increase adaptive immune
responses (10).
Previously, we observed that some young childrenwho received
the Arepanrix™ vaccine exhibited unusual avidity profiles after
vaccination (11), although in HIV-positive adults, high avidity
antibodies were maintained up to 6months after immunization
(12). Given the two major changes in vaccine formulation (addi-
tion of AS03 and reduced Ag dose), we wished to determine
if there were differences in the immune response after immu-
nization with unadjuvanted full-Ag dose versus AS03-adjuvanted
low-dose vaccines.
Typically, dose-sparing strategies use a fixed amount of the
adjuvant with varying Ag doses to identify the best formu-
lation. We took the same approach but with exaggerated Ag
dilutions with an influenza A/H3N2 split virion model Ag
(A/Uruguay/716/2007) to investigate the relationship between
Ag dose and AS03. We show that varying one or the other can
change the immune outcomes. High- and low-dose unadjuvanted
vaccines generated similar immune responses in BALB/c mice.
AS03-adjuvanted vaccines were able to generate superior humoral
responses and distinct cellular immune responses compared to
unadjuvanted vaccine.
Materials and Methods
Vaccine, Adjuvant, and Mouse Immunizations
Vaccine doses of 50 µl contained monovalent influenza
A/Uruguay/716/2007 H3N2 detergent-split inactivated Ag
(30 pg–3 µg HA content; GSK Vaccines, Ste-Foy, QC, Canada)
and one of two variants of AS03 (GSK Vaccines, Rixensart,
Belgium). AS03 is an Adjuvant System, which contains α-
tocopherol and squalene in an oil-in-water emulsion. In
human vaccines, AS03A contains 11.86mg α-tocopherol and
AS03B contains 5.93mg α-tocopherol. For this publication, the
quantities of the constituents in the murine doses of AS03A and
AS03B were 10-fold lower than the respective human doses. Eight-
to ten-week-old female BALB/c mice (Charles River Laboratories,
Montreal, QC, Canada) were immunized by injection into the
gastrocnemius muscle on days 0 and 21 (0.5 CC syringe with
28G 1/2 needle). Before each immunization, blood was collected
from the lateral saphenous vein. At 3weeks after the booster
immunization, mice were sacrificed; serum and splenocytes
were collected from each mouse and processed individually as
described below. All procedures were carried out in accordance
with guidelines of the Canadian Council on Animal Care, as
approved by the Animal Care Committee of McGill University.
Antibody Titer Measurement
Blood was collected in microtainer serum separator tubes (BD
Biosciences, Mississauga, ON, Canada). Cleared serum samples
were obtained following manufacturer’s protocol and stored at
 20°C until analysis.
Hemagglutination inhibition (HAI) and microneutralization
(MN) titers were measured in serum as previously
described (11, 13).
ELISA protocols were optimized (14, 15) to determine HA-
specific IgG concentration and avidity. Duplicate U-bottom
high-binding 96-well ELISA plates (Greiner Bio-one, Fricken-
hausen, Germany) were coated with recombinant HA protein
from A/Brisbane/10/2007 H3N2 (0.5 µg/ml) (Immune Technol-
ogy Corp., New York, NY, USA) and a standard curve of mouse
IgG antibodies (Sigma, St. Louis, MO, USA) in 100mM bicar-
bonate/carbonate buffer at pH 9.5 [50 µl/well, overnight (O/N)
at 4°C]. The A/Uruguay/716/2007 H3N2 vaccine strain used in
this study is an A/Brisbane/10/2007 H3N2-like strain and shares
100% homology with each other. Before and after each step,
wells were washed with PBS. Wells were blocked with 2% bovine
serum albumin (BSA; Sigma) in PBS-Tween 20 (0.05%; Fisher
Scientific, Ottawa, ON, Canada) (blocking buffer) (150 µl/well,
1 h at 37°C). Serum samples were diluted 1:50 in blocking buffer
and added to triplicate wells of duplicate plates (50 µl/well, 1 h at
37°C); blocking buffer was added to standard curves. Next, one
plate was incubated with 6M urea in PBS for 15min at room
temperature (RT), while standard curves and the second plate
were incubated with blocking buffer. After washing, plates were
blocked again (150 µl/well, 1 h at 37°C) and thenHRP-conjugated
anti-mouse total IgG antibodies (Jackson ImmunoResearch Lab-
oratories Inc., West Grove, PA, USA) diluted 1:10,000 in blocking
buffer was used (75 µl/well, 1 h at 37°C). Plates were detected
with 3,30,5,50-tetramethyl benzidine (TMB) substrate (Millipore,
Billerica, MA, USA) and stopped after 15min with 0.5M H2SO4.
Plates were read at 450 nm on an EL800microplate reader (BioTek
Instruments Inc., Winooski, VT, USA). The concentration of
HA-specific IgG antibodies was determined using the standard
curve included on each plate. The avidity index is calculated as
(IgG concentration remaining after urea incubation)/(total IgG
concentration) 100%.
Splenocyte Isolation
Spleens were excised, collected in Hank’s balanced salt solution
without calcium and magnesium (HBSS) (Wisent, St. Bruno, QC,
Canada), and processed individually. Homogenous cell suspen-
sions were prepared by passing organs through a 70 µm cell
strainer (BD Biosciences, Mississauga, ON, Canada). Cells were
treated with ACK buffer (0.15M NH4Cl, 1mM KHCO3, 0.1mM
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Na2EDTA; pH 7.2), and then washed with HBSS. Splenocytes
were resuspended in RPMI supplemented with 10% fetal bovine
serum (FBS), 1mMpenicillin/streptomycin (all fromWisent), and
0.5mM β-mercaptoethanol (Sigma) (complete RPMI, cRPMI).
Splenocyte Stimulation and Cell Proliferation
Assay
Splenocytes were seeded in duplicate in 96-well U-bottom plates
(BD Falcon, Mississauga, ON, Canada) at 106 cells in 200 µl with
cRPMI alone (unstimulated) or with A/Uruguay/716/2007 H3N2
split vaccine (2.5 µg/ml HA) in cRPMI. After 72 h at 37°C +5%
CO2, plates were spun down (300 g, 10min at RT) and super-
natant was collected and stored at 80°C until analysis. Cells were
pulsed with 1 µCi/well H3-Thymidine (MP Biomedical, Solon,
OH,USA) for an additional 18 h. After one freeze–thaw, cells were
harvested on glass–fiber filterswith aTomtec harvester 96 (Tomtec
Inc., Hamden, CT, USA) and H3-thymidine incorporation was
measured by scintillation counter (Wallac Microbeta Trilux 1450
beta-counter; Wallec, Turku, Finland). Cell proliferation val-
ues were expressed as stimulation index (SI); for each mouse
SI= (average Ag-stimulated cpm)/(average unstimulated cpm).
Quantitation of Cytokines in Supernatant
The concentrations of 16 cytokines and chemokines (IL-1α, IL-
1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-17, MCP-I,
IFNγ, TNFα, MIP-1α, GM-CSF, and RANTES) in culture super-
natants after 72 h stimulation in vitro were determined using Q-
Plex Mouse Cytokine – Screen (16-plex) multiplex ELISA follow-
ing the manufacturer’s guidelines (Quansys Biosciences, Logan,
UT, USA). Ag-stimulated supernatant samples for each mouse
were run as singlets. Unstimulated samples were pooled for each
group and run as singlets.
ELISpot Assays
Influenza HA-specific antibody secreting cells (ASCs) were deter-
mined using the ELISpotPlus for Mouse IgG kit (MabTech Inc.,
Mariemont, OH, USA) following Protocol I using biotinylated
Ag. Biotinylated HA was prepared using recombinant HA protein
from A/Brisbane/10/2007 H3N2 (Immune Technology Corp.).
Biotinylation was performed using the EZ-Link Micro Sulfo-
NHS-LC-Biotinylation kit (Thermo Scientific, Lafayette, CO,
USA) following the manufacturer’s protocol. Wells were coated
with mouse anti-IgG capture antibody according to the manu-
facturer’s protocol. Splenocytes (2.5 105 to 106 cells in 150 µl)
were added to duplicate wells and incubated for 16 h at 37°C+5%
CO2. Biotinylated HA protein (1 µg/ml), Streptavidin-alkaline
phosphatase (ALP), and nitroblue tetrazolium chloride/5-bromo-
4-chloro-3-indolyl phosphate (BCIP/NBT)-plus substrate were
used to detect HA-specific IgG ASCs according to the manufac-
turer’s protocol (MabTech Inc.). Plates were read using a CTL
series 3B ImmunoSpot analyzer (CTL Analyzers LLC, Cleveland,
OH, USA) with ImmunoSpot 4.0.3 software supplied by the
manufacturer.
To estimate numbers of memory B cells, splenocytes were stim-
ulated for 5 days ex vivo to generatememory B cell-derived plasma
cells before plating onto ELISpot plates as described above. The
stimulation protocol was modified from (16, 17); 4 106 spleno-
cytes were stimulated with 2 µg/ml CpG Prototype ODN 2006
(Hycult Biotech, PlymouthMeeting, PA, USA) and 50U/ml hIL-2
(kindly provided by Dr. Ciriaco A. Piccirillo, McGill University)
in 2ml cRPMI for 5 days. Cells were collected, washed, and seeded
onto pre-coated ELISpot plates as described above. Splenocytes
cultured without stimulation for 5 days were included as negative
controls, and were at baseline (data not shown).
Splenocyte Stimulation, Intracellular Staining,
and Flow Cytometry Analysis
Protocols weremodified fromMoris et al. (7) to analyze influenza-
specific T cell responses. Splenocytes from each mouse were
seeded in 96-well U-bottom plates (BD Biosciences) (106 cells
in 200 µl/well) and stimulated as singlets with anti-mouse CD28
(37.51) and CD49b (HMa2) antibodies for co-stimulation (both
from eBioscience, San Diego, CA, USA) at 2 µg/ml (background)
or both antibodies with A/Uruguay/716/2007 H3N2 split vaccine
(10 µg HA/ml) (Ag-stimulated) in cRPMI. Following 13 h at 37°C
+5% CO2, Brefeldin A (eBioscience) was added according to
manufacturer’s protocol and incubated for 5 h. As positive con-
trols, pooled splenocytes for each group were co-stimulated with
antibodies described above, and with phorbol myristate acetate
(PMA)+ ionomycin (2.5 and 5 µg/ml, respectively) and Brefeldin
A for 5 h. Control samples were stained and analyzed as described
below (data not shown). After incubation, cells were transferred
to V-bottom plates (BD Biosciences) for FC staining.
Antibodies used, the staining procedure and gating strategy are
described in Figure S1 in Supplementary Material. Briefly, cells
were stained for CD3, CD4, and CD8 on the surface and intracel-
lularly for IL-2, IL-5, IFNγ, and TNFα. Results are expressed as
the percentage of CD4+ and CD8+ T cells producing all com-
binations of the cytokines tested. Background (cells stimulated
with anti-CD28 and anti-CD49d antibodies only) was subtracted
from Ag-stimulated values (cells stimulated with antibodies and
A/Uruguay H3N2 split vaccine).
Statistical Analysis
For serum antibody titers and avidity, estimates of the geometric
mean ratios between groups and their 95% confidence intervals
(CI) were obtained using back-transformation on log10 values.
All experiments were analyzed by one-way analysis of variance
(ANOVA) followed by Tukey post-test to compare all possible
pairs of groups. Analyses were performed using GraphPad Prism
5.0 software.
Results
Adjuvanted, Low-Dose Vaccines Generate
Superior Antibody Responses than Unadjuvated
Vaccines
Two formulations of unadjuvanted high-Ag dose vaccines (3
and 6 µg/dose) were selected based on previous studies (18).
After one or two immunizations, mice produced comparable HAI
titers, which were significantly higher than the control groups
(Figures 1A,B).
Based on the Arepanrix™ vaccine and other mouse studies,
we selected 0.75 µg as the starting point for our low Ag for-
mulations (3, 18). After one immunization, mice vaccinated
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FIGURE 1 | Hemagglutination inhibition (HAI) titers in BALB/c mice
after one or two immunizations of unadjuvanted A/Uruguay/
716/2007 H3N2 split vaccine or AS03-adjuvanted dose-sparing
vaccines. Mice were immunized intramuscularly on days 0 and 21, and
sera from individual mice were analyzed. HAI titers of mice immunized
with AS03A-adjuvanted vaccines on days 21 (A) and 42 (B). HAI titers of
mice immunized with AS03A or AS03B-adjuvanted vaccines on days 21
(C) and 42 (D). On top of bars, * indicates a significant increase
(P<0.05) to negative “ ” group and ** indicates a significant increase
(P<0.05) to both negative “ ” and AS03A only control groups. For
(A,B), delta symbols (∆) on top of bars indicate a significant increase
(P<0.05) compared to mice immunized with 3 µg vaccine only. For
(C,D) significant differences between groups are denoted by brackets;
*P<0.05; **P<0.01; ***P<0.001. For (A,B) data represent 4–12
individual mice per group combined from two independent studies. For
(C,D), data represent 4–17 or 4–25 mice per group combined from three
or four independent studies, respectively. Geometric means and 95%
confidence intervals are shown.
with 0.75 µg+AS03A produced significantly higher HAI titers
than either high-dose unadjuvanted vaccine (3 or 6 µg/dose;
Figure 1A). Progressively lower doses of Ag administered with
AS03A were able to generate detectable HAI titers after one
immunization, but titers began to fall off at doses below 0.06 µg
(Figure 1A).
Booster immunization increasedHAI titers overall (Figure 1B).
Mice immunized with low Ag dose (0.003–0.75 µg/dose) with
AS03A produced significantly higher HAI titers than 3 µg with-
out adjuvant (Figure 1B). Interestingly, although no response
was detected after one dose, titers increased remarkably in the
0.003 µg+AS03A group after boosting (Figure 1B).
We next compared AS03A with half the amount of adjuvant
(AS03B) to unadjuvanted formulations. After a single immuniza-
tion, unadjuvanted low-dose (0.03–0.003 µg) vaccines elicited low
but detectable HAI titers (Figure 1C). Generally, use of the adju-
vant increased antibody titers. AS03B functioned as efficiently as
AS03A with 0.03 µg Ag, but at the lower dose (0.003 µg), AS03B
generated a better response than AS03A in terms of HAI anti-
bodies (Figure 1C). After booster immunization, 0.03 or 0.003 µg
Ag with AS03A or AS03B generated similar HAI titers, which
were higher than unadjuvanted vaccine (Figure 1D). Unadju-
vanted low-dose vaccines tended to generate lower titers than the
unadjuvanted high-dose formulation.
We were unable to reproducibly detect HAI titers after two
immunizations at Ag doses of 0.0003 µg with AS03A or AS03B
in our mouse model (Figures 1C,D). These very low Ag doses
also failed to generate detectable immune responses by ELISA,
MN assays, ELISpot, and lymphoproliferation in restimulated
splenocytes (data not shown). Therefore, we focused on low Ag
doses of 0.03 and 0.003 µg in our subsequent studies.
Similar to the HAI results, two immunizations of AS03-
adjuvanted, low-dose vaccines tended to induce higher concen-
trations of influenza HA-specific IgG by ELISA than unadju-
vanted vaccine (Figure 2A). The strength of antibody binding
(avidity) was not significantly changed in response to Ag dose
or use of AS03 adjuvant (Figure 2B). After two immunizations
with 0.03 µg+AS03A/B or 0.003 µg+AS03A/B, MN titers were
equivalent or superior to those observed with unadjuvanted for-
mulations (Figure 2C).
These data demonstrate that strong serum antibody responses
can be elicited in BALB/c mice with 100- or 1000-fold lower
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FIGURE 2 | Influenza HA-specific IgG concentrations, antibody avidity,
and microneutralization (MN) titers in BALB/c mice after one or two
immunizations of unadjuvanted A/Uruguay/716/2007 H3N2 split vaccine
or AS03-adjuvanted dose-sparing vaccines. Mice were immunized
intramuscularly on days 0 and 21, and sera from individual mice were analyzed.
Anti-HA IgG concentrations (A) and antibody avidity (B) measured by ELISA,
and MN titers (C) were determined on day 42. On top of bars, * indicates a
significant increase (P<0.05) to negative “ ” group and ** indicates a
significant increase (P<0.05) to both negative “ ” and AS03A only control
groups. Significant differences between groups are denoted by brackets;
*P<0.05; **P<0.01; ***P<0.001. For (A,B), data represent 4–10 mice per
group combined from three independent studies. For (C), data represent 4–12
mice per group combined from three independent studies. Geometric means
and 95% confidence intervals are shown. ND, not detected.
Ag than a high-Ag dose and that AS03 can increase serological
responses even at very low Ag doses.
Adjuvanted Low-Dose and Unadjuvanted
Vaccines Generate Distinct Antigen-Specific
Cytokine Profiles
All Ag-containing vaccines elicited detectable levels of Ag-
specific lymphoproliferation in ex vivo stimulated splenocytes
(Figure 3A). No statistical differences in proliferation were
observed between any of the formulations so the immune
microenvironment was further assessed by measuring
cytokine/chemokine concentrations in culture supernatants.
Unadjuvanted vaccine at all Ag doses generated similar lev-
els of all cytokines tested (Figure 3). However, adjuvanted
low-dose vaccines generated very different influenza-specific
cytokine milieus compared to unadjuvanted formulations. Some
cytokines/chemokines, such as IL-4, IL-5, IL-10, and MCP-
1/CCL2 were produced at similar levels in all groups (Figure 3),
while others such as IL-2, IL-3, IL-6, IFNγ, RANTES/CCL5,
IL-17, and GM-CSF were more strongly induced by the low-
dose adjuvanted vaccines (Figure 3). The cytokine/chemokine
responses are summarized in Table 1. AS03 tended to change
the balance of cytokine responses by activating different arms of
the immune response (Th1, Th2, Th17, and growth promoting
cytokines) (Table 1). In comparison, all unadjuvanted groups
produced similar cytokine profiles. No significant differences in
the levels of IL-1α, IL-1β, TNFα, andMIP-1αwere observed (data
not shown).
We focused our next studies on immune responses at the cel-
lular level. Given that no significant differences in proliferation or
cytokine production were observed between unadjuvanted vac-
cines at different Ag doses, we focused our analysis on unadju-
vanted high-dose versus AS03-adjuvanted low-dose formulations.
Adjuvanted Low-Dose Vaccines Generate More
ASCs than High-Dose Unadjuvated Vaccine
ELISpots were used to enumerate influenza-HA specific IgGASCs
in splenocytes (i.e., plasma cells), and memory B cell-derived
plasma cells (i.e., memory ASCs) following in vitro differentiation.
Low levels of ASCs and memory ASCs were detectable in mice
immunized with unadjuvanted vaccine (Figures 4A,C,E). Mice
immunized with 0.03 µg+AS03A/B had higher numbers of ASCs
(Figures 4A,E) and memory ASCs (Figure 4C). At the lowest Ag
dose (0.003 µg+AS03A/B), the ASC (Figures 4A,E) and memory
ASC response (Figure 4C) were comparable to that seen in mice
receiving unadjuvanted vaccine. The mean spot size in these
assays is correlated with the amount of antibody secreted. The
adjuvanted low-dose groups tended to secret more antibodies per
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FIGURE 3 | Influenza-specific splenocyte proliferation and cytokine
production after two immunizations of unadjuvanted
A/Uruguay/716/2007 H3N2 split vaccine or AS03-adjuvanted
dose-sparing vaccines. BALB/c mice were immunized intramuscularly on
days 0 and 21, and splenocytes were isolated from individual mice on day 42.
(Continued)
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FIGURE 3 | Continued
Splenocytes were stimulated ex vivo with media (unstimulated background) or
with A/Uruguay H3N2 split vaccine. Culture supernatant was collected after 72 h
and cells were pulsed with H3-Thymidine for an additional 18 h. Cell proliferation
(A) is shown as a stimulation index (SI). The line represents the mean +2 SDs of
the negative control group. The concentrations of cytokines and chemokines in
culture supernatants were determined using Q-Plex Mouse Cytokine – Screen
(16-plex) multiplex ELISA and are summarized in Table 1: (B) IL-2, (C) IL-10,
(D) IL-12, (E) IFNγ, (F) RANTES/CCL5, (G) IL-4, (H) IL-5, (I) IL-17, (J) IL-6,
(K) GM-CSF, (L) IL-3, (M) MCP-1/CCL2. The line represents the mean +2 SDs
of the cytokine concentration of unstimulated samples for all groups. On top of
bars, * indicates a significant increase (P<0.05) to negative “ ” group and **
indicates a significant increase (P<0.05) to both negative “ ” and AS03A only
control groups. Significant differences between different groups are denoted by
brackets; *P<0.05; **P<0.01; ***P<0.001. Data represent mean and SEs of
3–19 mice per group combined from three independent studies.
TABLE 1 | Summary of influenza-specific cytokine responses in the supernatants of restimulated splenocytes after two immunizations of unadjuvanted
A/Uruguay/716/2007 H3N2 split vaccine or AS03-adjuvanted dose-sparing vaccines.
Category Cytokine High-Ag dose Low Ag dose
Unadjuvanteda Unadjuvanteda,b Adjuvanteda,b
3 μg 0.03 or 0.003 μg 0.03 or 0.003 μg+AS03A/B
T cell proliferation IL-2 ++
Anti-inflammatory IL-10 ++ ++ ++
Th1 IL-12 ++
IFNγ ++
RANTES/CCL5 ++
Th2 IL-4 ++ ++ ++
IL-5 ++ ++ ++
Th17 IL-17 ++
IL-6 ++
Growth promoting and chemokines GM-CSF + + ++
IL-3 + + ++
MCP-1/CCL3 + + +
aThe “+” sign indicates a significant increase (P< 0.05) to negative “ ” group and “++” indicates a significant increase (P<0.05) to both negative “ ” and AS03A only control groups.
bThe “+” or “++” signs indicate a significant difference by 0.03 and/or 0.003 µg Ag dose with or without AS03.
ASC or memory ASC than unadjuvanted vaccine (Figures 4B,D).
These data suggest the adjuvanted low-dose formulations induced
greater numbers of influenza-specific plasma cells and potentially
memory B cell-derived ASCs that secreted more antibody per cell
compared to the high-dose unadjuvanted vaccine.
AS03B-Adjuvanted Low-Dose Vaccines Produce
More Influenza-Specific CD4+ and CD8+ T Cells
We investigated influenza-specific cytokine production in spleno-
cytes by examining CD4+ or CD8+ T cells that produced IL-
2, IL-5, TNFα, and IFNγ cytokines by flow cytometry (FC)
(Figure S1 in Supplementary Material). Immunization with
0.003 µg+AS03B generated the highest percentage of Ag-specific
CD4+ (Figure 5A; Figure S2 in Supplementary Material) and
CD8+ (Figure 6A; Figure S3 in Supplementary Material) T cells
expressing any combination of the four cytokines tested. Gener-
ally, formulations with AS03B tended to generate more cytokine-
producing cells than with AS03A (Figures 5A and 6A).
Ag-specific T cells can be categorized according to the number
of cytokines they produced. Most CD4+ and CD8+ T cells were
single positive for one of the four cytokines (Figures 5B and 6B).
With all formulations, over 90% of cytokine-producing CD4+ T
cells secreted a single cytokine (Figure 5B). For CD8+ T cells,
AS03A-adjuvanted low-dose vaccines induced similar levels of
poly-functional T cells (expressing two or more cytokines) as
high-dose vaccine, which tended to be higher than that observed
with AS03B-adjuvanted formulations (Figure 6B).
Ag-specific, single positive T cells can be further categorized
according to the cytokine produced. Most single positive CD4+
T cells in the high-dose unadjuvanted and AS03A-adjuvanted
low-dose groups expressed IL-2, whereas the AS03B-adjuvanted
groups produced more IFNγ-secreting cells (Figure 5C). In all
groups except 0.003 µg+AS03A, most single positive CD8+
T cells expressed IFNγ, followed by a smaller percentage
of IL-2-secreting cells (Figure 6C). Interestingly, mice given
0.003 µg+AS03A tended to generate relatively equal propor-
tions of IL-2 and IFNγ expressing CD8+ T cells (Figure 6D),
although this group tended to generate fewer total respond-
ing cells (Figure 6A). Compared to high-dose vaccine, the
0.003 µg+AS03B recipients had significantly higher percentages
of CD4+ and CD8+ T cells single positive for IFNγ (Figures 5D
and 6D). There were no significant differences in single positive
IL-2 (Figures 5E and 6E), IL-5, or TNFα (data not shown) pro-
ducing cells or any combination of double or triple positive cells,
and no Ag-specific, quadruple positive cells were observed (data
not shown).
Discussion
We demonstrate that use of AS03 can markedly change both the
magnitude and pattern of vaccine-induced humoral and cellu-
lar immune responses in mice. Nanogram quantities of unad-
juvanted vaccine were sufficient to induce Ag-specific immune
responses that were, in some respects, comparable to those
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FIGURE 4 | Generation of influenza HA-specific antibody secreting
cells (ASCs) and memory B cell-derived ASCs after two
immunizations of unadjuvanted A/Uruguay/716/2007 H3N2 split
vaccine or AS03-adjuvanted dose-sparing vaccines. BALB/c mice
were immunized intramuscularly on days 0 and 21, and splenocytes were
isolated from individual mice on day 42. The number (A) and mean spot
size (B) of HA-specific IgG antibody secreting cells (ASCs) were
determined by ELISpot. Following ex vivo stimulation, the number (C) and
mean spot size (D) of memory B cell-derived HA-specific IgG ASCs were
determined by ELISpot. Representative ELISpot wells are shown in
(E). On top of bars, * indicates a significant increase (P<0.05) to negative
“ ” group and ** indicates a significant increase (P<0.05) to both
negative “ ” and AS03A only control groups. Significant differences
between groups are denoted by brackets; *P<0.05; **P<0.01;
***P<0.001. Data represent mean and SEs of 4–12 mice per group
combined from two independent studies.
induced by high-dose vaccine. However, in the presence of AS03,
even very low-dose (0.03–0.003 µg/dose) formulations elicited
superior humoral and distinct cellular immune responses com-
pared to unadjuvanted vaccine. Given that cell-mediated immu-
nity is increasingly recognized to be important in protecting
against influenza viral infection (19), these results suggest that
over-reliance on serum antibody responses may not identify opti-
mal vaccine formulations.
This is the first detailed pre-clinical investigation of the
humoral and cellular immune responses to extreme dose-sparing
with AS03. As little as 3 ng (0.003 µg) of A/Uruguay H3N2 model
Ag was sufficient to induce excellent responses with or without
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FIGURE 5 | Influenza-specific cytokine-producing CD4+ T cells in
splenocytes after two immunizations of unadjuvanted
A/Uruguay/716/2007 H3N2 split vaccine or AS03-adjuvanted
dose-sparing vaccines. BALB/c mice were immunized intramuscularly
on days 0 and 21, and splenocytes were isolated from individual mice on
day 42. Splenocytes were stimulated ex vivo with A/Uruguay H3N2 split
vaccine and co-stimulatory antibodies, then analyzed by flow cytometry for
CD4+ T cells that produced a combination of IL-2, IL-5, IFNγ, or TNFα
cytokines. The gating strategy is described in Figure S2 in Supplementary
Material and representative dot plots are shown in Figure S3 in
Supplementary Material. The percentage of total responding CD4+ T cells
that expressed any combination of the four cytokines (A). The distribution
of the number of individual cytokines produced by total responding CD4+
T cells (B). The distribution of the specific cytokines produced by
single-positive CD4+ T cells (C). The percentage of CD4+ T cells that
were single positive for IFNγ (D) or IL-2 (E). On top of groups, ** indicates a
significant increase (P<0.05) to both negative “ ” and AS03A only control
groups. Significant differences between groups are denoted by brackets;
*P<0.05; **P<0.01; ***P<0.001. Data represent mean and SEs of 3–5
mice per group. An outlier in the AS03A only control group (denoted in
brackets) was beyond the mean +3 SDs of the remainder of the group,
and was omitted from analysis.
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FIGURE 6 | Influenza-specific cytokine-producing CD8+ T cells in
splenocytes after two immunizations of unadjuvanted
A/Uruguay/716/2007 H3N2 split vaccine or AS03-adjuvanted
dose-sparing vaccines. BALB/c mice were immunized intramuscularly
on days 0 and 21, and splenocytes were isolated from individual mice on
day 42. Splenocytes were stimulated ex vivo with A/Uruguay H3N2 split
vaccine and co-stimulatory antibodies, then analyzed by flow cytometry for
CD8+ T cells that produced a combination of IL-2, IL-5, IFNγ, or TNFα
cytokines. The gating strategy is described in Figure S2 in Supplementary
Material and representative dot plots are shown in Figure S4 in
Supplementary Material. The percentage of total responding CD8+ T cells
that expressed any combination of the four cytokines (A). The distribution
of the number of individual cytokines produced by total responding CD8+
T cells (B). The distribution of the specific cytokines produced by
single-positive CD8+ T cells (C). The percentage of CD8+ T cells that
were single positive for IFNγ (D) or IL-2 (E). On top of groups, ** indicates a
significant increase (P<0.05) to both negative “ ” and AS03A only control
groups. Significant differences between groups are denoted by brackets;
*P<0.05; **P<0.01; ***P<0.001. Data represent mean and SEs of 3–5
mice per group. An outlier in the AS03A only control group (denoted in
brackets) was beyond the mean +3 SDs of the remainder of the group,
and was omitted from analysis.
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AS03. Our findings are similar to those recently reported, which
found that 0.03–0.04 µg of influenza vaccines intramuscularly
injected with various adjuvants could induce Ag-specific humoral
and cellular immune responses, and protect against viral infection
(20, 21). In contrast to these studies, we varied both Ag and
adjuvant dose and performed detailed analyses of both B and T
cell responses following vaccination.
The IgG avidity result is particularly surprising since the devel-
opment of high avidity antibodies is thought to require both
sufficient time and presence of Ag (22). Antibodies with compa-
rable avidity were generated with high- and low-dose Ag with or
without adjuvant. This was unexpected and is possibly a testament
to the remarkable efficiency of the BALB/cmouse immune system
or the immunogenicity of the A/Uruguay H3N2 split virion Ag
used. Future studies could use different mouse strains to further
investigate antibody avidity. In contrast, human trials with a sim-
ilar oil-in-water adjuvant, MF59 and A/California/07/2009 H1N1
split-virus Ag in a dose-sparing formulation (7.5 µg+MF59)
increased antibody avidity compared to standard unadjuvanted
vaccine (15 µg) (23, 24). Another consideration is that relatively
massive Ag doses are administered to mice in most pre-clinical
vaccine studies. On a body-weight basis, our 0.003 µg dose in a
20 gmouse translates into an ~10 µg dose in a 70 kg human, which
is close to the standard influenza vaccine dosage per strain. Our
data raise the question of whether or not the doses routinely used
in pre-clinical studies should be re-evaluated.
The superior performance of the adjuvanted, low-dose for-
mulations in the induction of ASCs that secrete more anti-
bodies per cell was intriguing. The presence of greater num-
bers of highly active plasma cells likely accounts for the
higher serum HAI and ELISA antibody titers observed in the
0.03 µg+AS03A/B groups, although MN titers were not simi-
larly elevated. Surprisingly, unadjuvanted and the lowest Ag dose
groups (0.003 µg+AS03A/B) generated very low numbers (close
to background) of ASCs and memory ASCs in the spleen, but
exhibited robust serum antibody titers. It would be interesting
to investigate the presence of ASCs in other compartments (e.g.,
bone marrow) since plasma cells and memory B cells eventually
track to the bone marrow late in the immune response (22). Dif-
ferences in cell traffickingmight therefore account for the seeming
discrepancy between the low numbers of ASCs, but high serum
antibody titers. The maintenance of long-term humoral memory
is influenced by several factors including the presence of sufficient
Ag (25). Indeed in our study, splenocytes from the lowest dose
groups (0.003 µg+AS03A/B) had fewer ASCs and memory ASCs
than groups immunized with 0.03 µg suggesting that Ag dose
plays a role in our model in the generation of plasma andmemory
B cells. There were, however, no major differences in the level of
antibody secretion per cell in the two adjuvanted low-dose groups.
Unadjuvanted and low-dose adjuvanted vaccines also induced
distinct cytokine profiles in restimulated splenocytes. Compared
to adjuvanted, low-dose vaccines, the unadjuvanted groups tended
to produce higher levels of Th2 cytokines such as IL-4 and IL-5,
as well as IL-10 that can promote B cell proliferation. However,
serum antibody levels and the number of ASCs in the unad-
juvanted groups were not higher than those seen in the adju-
vanted, low-dose groups. Together, these observations suggest a
Th2-biased response with ineffective antibody production. This
apparent paradox might be explained by the activation of a
broader range of cytokines in the adjuvanted vaccine groups
leading to greater overall vaccine-specific responses. For example,
the splenocytes of AS03-containing groups produced higher levels
of IL-2 and IL-6 thereby suggesting activation of more T cells
and greater differentiation of follicular helper T cells, respectively
(26, 27). Furthermore, IL-6 also plays a role in the maturation
of B cells into ASCs. The AS03-adjuvanted formulations also
induced higher levels of IFNγ and RANTES/CCL5, the latter
acting through the CCR5 receptor to promote development of
IFNγ-producing Th1 cells (26). Surprisingly, the unadjuvanted
low-dose vaccine tended to induce the highest level of IL-12, a
Th1-promoting cytokine, although this difference did not reach
statistical significance. Therefore, in our mouse model, both
the unadjuvanted and adjuvanted formulations had the poten-
tial to induce cytokines/chemokines associated with Th1-type
responses. Finally, only the adjuvanted formulations were found
to induce Th17 type (IL-17 and IL-6) and growth promoting
(GM-CSF and IL-3) cytokines. In summary, we found that the
unadjuvanted vaccines could induce both Th1- and Th2-type
responses, while AS03-adjuvanted vaccines induced Th1, Th2,
Th17, and growth promoting cytokine/chemokine production
in the restimulated splenocytes. Activation of this broad range
of cytokines/chemokines by the adjuvanted vaccines likely con-
tributed to the stronger Ag-specific immune responses generated.
Historically, little attention was paid to adjuvant dose except
in the context of adverse events, with greater adjuvant doses
tending to cause more reactions (28, 29). Little consideration
was given to the idea that different doses of adjuvant might
alter the pattern of the immune response induced. In a single
clinical trial that varied the doses of both MF59 (full, half, or
quarter) and trivalent inactivated influenza vaccine (15 or 30 µg)
in elderly subjects, Della Cioppa et al. found that more adjuvant
tended to induce higher HAI titers but had no effect on the Ag-
specific CD4T cell response (30). In ourmodel, AS03A andAS03B
(full- and half-dose, respectively) induced similar serum antibody
profiles. However, the AS03B-adjuvanted formulations tended to
produce higher levels of most of the cytokines/chemokines mea-
sured compared to AS03A. Formulations with AS03B (especially
the 0.003 µg/dose) also generated more influenza-specific CD4+
and CD8+ T cells than the unadjuvanted or AS03A-adjuvanted
vaccines, although these cells were primarily single positive for
IFNγ. However, we found that the low-dose vaccines formulated
with AS03A tended to generate more influenza-specific poly-
functional CD8+ T cells compared to AS03B. Poly-functional
T cells generally express higher levels of cytokines per cell and
are considered to be functionally superior to single-cytokine-
producing cells (31). Additional studies are needed to determine
the functional significance of the mono-functional versus poly-
functional T cells induced by these different formulations in our
vaccine model.
In human studies of PBMCs isolated after AS03-adjuvanted
vaccine administration, an increase in Ag-specific CD4+ T cells
is usually observed in the absence of increasing CD8+ T cells
responses (7, 32, 33). In contrast, we observed both CD4+ and
CD8+ T cell responses similar to the findings of other mouse
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studies. For example, studies from the Boivin laboratory showed
that two immunizations of AS03-adjuvanted influenza vaccine (at
3 µg/dose) produced detectable Ag-specific CD4+ and CD8+ T
cells, which tended to be greater than responses in control groups,
although statistical differences were not observed (18, 34). We
found that reductions inAgdosewith the samedose ofAS03 could
markedly increase T cell responses.
Clearly, we show that greater attention should be paid to the
balance of Ag and adjuvant in vaccine formulations to fully under-
stand vaccine efficacy. However, given the known differences
in T cell responses in humans versus mice, our observations
in the very low-dose mouse model may not be predictive of
responses in humans. The majority of adult humans have been
previously exposed to various strains of influenza, which is unlike
the immunologically naïve mice in our studies. In human studies
with AS03, vaccine-specific CD8+ T cells were detected at all
timepoints including pre-immunization, but vaccination failed to
significantly increase the Ag-specific CD8 responses (32, 33). In
naïve mice, we observe an increase in Ag-specific CD4+ and
CD8+ T cell responses after vaccination. Indeed, the two-dose
vaccination schedule that we use in our study is the same as that
used in immunologically naïve infants. As a result, our obser-
vations may be more relevant to this population, rather than
the response in primed adults who mainly receive a single dose.
Finally, AS03 is thought to function primarily through the induc-
tion of cytokines (low level inflammation) at the site of injection
(10) but the mouse and human inflammatory responses can be
very different as was recently demonstrated in a comprehensive
transcriptomic analysis (35). Therefore, the broad activation of
cytokines we observed in groups given AS03-adjuvanted formu-
lations may also be specific to our mouse model.
The current study has additional limitations; for example, we
have not yet tested whether or not the different immune response
patterns correlate with protection from influenza challenge. These
studies are currently underway. The A/Uruguay H3N2 split virion
Ag used in this study is also relatively more immunogenic in
mice than Ag prepared from other influenza strains (unpublished
observations). Therefore, our results may not extrapolate to other
vaccine formulations and additional studies are warranted to test
this. Although Ag doses in mouse influenza vaccine studies typ-
ically range from 3 to 15 µg, we acknowledge that our selection
of 3 µg as the high-dose vaccine formulation was entirely arbi-
trary. As noted above, our 3 µg dose does not correspond well
with the 15 µg Ag dose routinely used in human vaccines on
a body-weight basis. Similarly, our selection of 25 µl/12.5 µl of
AS03A/B was based upon previous mouse studies (18, 36) but is
also arbitrary and is much larger (350) than the corresponding
dose (by volume) used in humans for intramuscular injection
(250 µl) on a body-weight basis (3).
In the event of an influenza pandemic, there will be great
pressure to deliver the largest number of vaccine doses as quickly
as possible. Our data suggest that both Ag and adjuvant-sparing
strategies may make important contributions to optimization
efforts from both immunologic and economic standpoints. We
show that differences in both influenza Ag and adjuvant dose can
significantly alter the immune response pattern following vacci-
nation; findings that may be very relevant to the development of
better vaccines. These observations also raise important questions
about the use of “standard” doses of both Ag and adjuvants in
pre-clinical vaccine studies in mice.
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